Moderna Inc

MRNA: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$764.00DhrxGmdkjxfm

Moderna Earnings: High-Level Long-Term Guidance Fits Our View; Maintaining $227 Valuation

Moderna reported third-quarter results that were weaker than we had anticipated, largely due to significant manufacturing resizing expenses to allow the firm to adjust to the endemic phase of COVID-19 but retain more flexibility in the future.

Sponsor Center